• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Bacterial (Pyogenic) Meningitis - Pipeline Review, H2 2012 Product Image

Bacterial (Pyogenic) Meningitis - Pipeline Review, H2 2012

  • Published: December 2012
  • 58 pages
  • Global Markets Direct

Bacterial (Pyogenic) Meningitis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Bacterial (Pyogenic) Meningitis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bacterial (Pyogenic) Meningitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacterial (Pyogenic) Meningitis. Bacterial (Pyogenic) Meningitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bacterial (Pyogenic) Meningitis.
- A review of the Bacterial READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Bacterial (Pyogenic) Meningitis Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Bacterial (Pyogenic) Meningitis 8
Bacterial (Pyogenic) Meningitis Therapeutics under Development by Companies 10
Bacterial (Pyogenic) Meningitis Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Bacterial (Pyogenic) Meningitis Therapeutics – Products under Development by Companies 15
Bacterial (Pyogenic) Meningitis Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Bacterial (Pyogenic) Meningitis Therapeutics Development 17
Novartis AG 17
Pfizer Inc. 18
GlycoVaxyn AG 19
Sinovac Biotech Ltd. 20
China National Pharmaceutical Group Corporation 21
Bacterial (Pyogenic) Meningitis – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Meningitis Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Quadrivalent Meningococcal Conjugate Vaccine (MCV4) - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
MnB rLP2086 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
acetaminophen - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Glycerol + Paracetamol - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Bexsero - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Bexsero - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Amphotericin B + Fluconazole - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
dexamethasone beloxil - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Meningococcal Group B Meningitis Vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
rLP2086 + Repevax - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Conjugated Meningococcal C Vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Pneumococcal Vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Pneumococcal Vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Vi-CRM197 PCMV - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Bacterial (Pyogenic) Meningitis Therapeutics – Drug Profile Updates 49
Bacterial (Pyogenic) Meningitis Therapeutics - Dormant Products 52
Bacterial (Pyogenic) Meningitis – Product Development Milestones 53
Featured News & Press Releases 53
Feb 07, 2012: Novartis's Pivotal Study Confirms Potential Of Candidate Vaccine Bexsero To Help Protect Infants Against Devastating Meningococcal Serogroup B Disease 53
Jun 09, 2011: Novartis's Bexsero Shows Significant Potential In Providing Broad Coverage Against Meningococcal Serogroup B Infections 54
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Tables
Number of Products Under Development for Bacterial (Pyogenic) Meningitis, H2 2012 8
Products under Development for Bacterial (Pyogenic) Meningitis – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Novartis AG, H2 2012 17
Pfizer Inc., H2 2012 18
GlycoVaxyn AG, H2 2012 19
Sinovac Biotech Ltd., H2 2012 20
China National Pharmaceutical Group Corporation, H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
Bacterial (Pyogenic) Meningitis Therapeutics – Drug Profile Updates 49
Bacterial (Pyogenic) Meningitis Therapeutics – Dormant Products 52

List of Figures
Number of Products under Development for Bacterial (Pyogenic) Meningitis, H2 2012 8
Products under Development for Bacterial (Pyogenic) Meningitis – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos